1. Home
  2. ZGN vs IDYA Comparison

ZGN vs IDYA Comparison

Compare ZGN & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ermenegildo Zegna N.V.

ZGN

Ermenegildo Zegna N.V.

HOLD

Current Price

$14.32

Market Cap

3.5B

ML Signal

HOLD

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$35.49

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZGN
IDYA
Founded
1910
2015
Country
Italy
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.5B
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
ZGN
IDYA
Price
$14.32
$35.49
Analyst Decision
Buy
Strong Buy
Analyst Count
4
16
Target Price
$11.28
$52.86
AVG Volume (30 Days)
1.3M
1.4M
Earning Date
03-20-2026
05-06-2026
Dividend Yield
1.22%
N/A
EPS Growth
N/A
61.90
EPS
N/A
N/A
Revenue
N/A
$218,710,000.00
Revenue This Year
$5.17
N/A
Revenue Next Year
$7.89
$201.05
P/E Ratio
$25.94
N/A
Revenue Growth
N/A
3024.43
52 Week Low
$7.61
$21.33
52 Week High
$15.44
$40.58

Technical Indicators

Market Signals
Indicator
ZGN
IDYA
Relative Strength Index (RSI) 61.01 52.07
Support Level $9.89 $32.85
Resistance Level $14.58 $38.17
Average True Range (ATR) 0.64 1.52
MACD 0.06 -0.39
Stochastic Oscillator 86.67 11.15

Price Performance

Historical Comparison
ZGN
IDYA

About ZGN Ermenegildo Zegna N.V.

Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of revenue from the Zegna segment.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: